Sanofi and Regeneron Gain an Edge in Cholesterol Drug Race
This article is for subscribers only.
Regeneron Pharmaceuticals Inc. and Sanofi may get a head start on their biggest competitor in bringing a new class of cholesterol drugs to the U.S. market.
The U.S. Food and Drug Administration has until July 24 to make a decision on the companies’ application to market their jointly developed drug alirocumab, Regeneron and Sanofi said in a statement.